Close Menu

NEW YORK – Quest Diagnostics reported today that its second quarter revenues were down 6 percent year over year.

For the three months ended June 30, total revenues reached $1.83 billion, down from $1.95 billion a year ago, and matching the consensus Wall Street estimate of $1.83 billion.

Quest Diagnostic Information Services revenues fell by around 6 percent to $1.76 billion from $1.87 billion in Q2 2019. Test volume declined by 18 percent year over year.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.


As worldwide COVID-19 cases continue to rise, there is a significant need to increase testing and population surveillance capacity.

Sponsored by

This webinar will present a case study from in vitro diagnostics developer SpeeDx on its experience building a complete sample-to-result workflow — encompassing instrumentation and data analysis software — for its qPCR-based ResistancePlus MG Mycoplasma genitalium assay.